Selective inhibition of cancer cell invasion by a geranylgeranyltransferase-I inhibitor

Clinical and Experimental Metastasis

Volumn 20, Issue 6, 2003, Pages 561-567

  Kusama, Toshiyuki ^a,c   Mukai, Mutsuko ^a   Tatsuta, Masaharu ^b   Matsumoto, Yoshirou ^a   Nakamura, Hiroyuki ^a   Inoue, Masahiro ^a  

^a OSAKA MEDICAL CENTER FOR CANCER AND CARDIOVASCULAR DISEASES   (Japan)

^b UNIVERSITY OF YAMANASHI   (Japan)

^c Osaka Medical College   (Japan)

Author keywords

Farnesyltransferase; Geranylgeranyltransferase; HMG CoA reductase inhibitor; Invasion; Rho

Indexed keywords

ANTIMETASTATIC AGENT; GERANYLGERANYLTRANSFERASE I; GERANYLGERANYLTRANSFERASE I INHIBITOR; GGTI 298; HYDROXYMETHYLGLUTARYL COENZYME A REDUCTASE INHIBITOR; MEVINOLIN; N [[5 [(2 AMINO 3 MERCAPTOPROPYL)AMINO][1,1' BIPHENYL] 2 YL]CARBONYL]METHIONINE METHYL ESTER; PROTEIN FARNESYLTRANSFERASE INHIBITOR; RAS PROTEIN; TRANSFERASE; TRANSFERASE INHIBITOR; UNCLASSIFIED DRUG;

ANIMAL CELL; ARTICLE; CANCER CELL; CELL INVASION; CELL STRUCTURE; COLON CARCINOMA; CONCENTRATION RESPONSE; CONTROLLED STUDY; CYTOSOL; DRUG EFFECT; ENZYME ACTIVITY; ENZYME INHIBITION; HUMAN; HUMAN CELL; IN VITRO STUDY; METASTASIS INHIBITION; NONHUMAN; PRENYLATION; PROTEIN LOCALIZATION; RAT; SIGNAL TRANSDUCTION;

ALKYL AND ARYL TRANSFERASES; BENZAMIDES; CELL DIVISION; COLONIC NEOPLASMS; ENZYME INHIBITORS; HUMANS; METHIONINE; MEVALONIC ACID; NEOPLASM INVASIVENESS; PANCREATIC NEOPLASMS; PROTEIN ISOPRENYLATION; SIGNAL TRANSDUCTION; TUMOR CELLS, CULTURED;

EID: 0142029984     PISSN: 02620898     EISSN: None     Source Type: Journal    
DOI: 10.1023/A:1025898316728     Document Type: Article

References (23)

1. Hall A. Rho GTPases and the actin cytoskeleton. Science 1998; 279 (5350): 509-14.
2. Elson CE, Peffley DM, Hentosh P, Mo H. Isoprenoid-mediated inhibition of mevalonate synthesis: Potential application to cancer. Proc Soc Exp Biol Med 1999; 221 (4): 294-311.
3. Zhang FL, Casey PJ. Protein prenylation: Molecular mechanisms and functional consequences. Ann Rev Biochem 1996; 65: 241-69.
4. Kusama T, Mukai M, Iwasaki T et al. Inhibition of epidermal growth factor-induced RhoA translocation and invasion of human pancreatic cancer cells by 3-hydroxy-3-methylglutaryl-coenzyme A reductase inhibitors. Cancer Res 2001; 61 (12): 4885-91.
5. Kusama T, Mukai M, Iwasaki T et al. 3-hydroxy-3-methylglutaryl-coenzyme A reductase inhibitors reduce human pancreatic cancer cell invasion and metastasis. Gastroenterology 2002; 122 (2): 308-17.
6. 2-M enrichment in A549 cells. Cancer Res 1997; 57 (10): 1846-50.
7. Mazet JL, Padieu M, Osman H et al. Combination of the novel farnesyltransferase inhibitor RPR130401 and the geranylgeranyltransferase-1 inhibitor GGTI-298 disrupts MAP kinase activation and G(1)-S transition in Ki-Ras-overexpressing transformed adrenocortical cells. FEBS Lett 1999; 460 (2): 235-40.
8. Sun J, Qian Y, Hamilton AD, Sebti SM. Both farnesyltransferase and geranylgeranyltransferase I inhibitors are required for inhibition of oncogenic K-Ras prenylation but each alone is sufficient to suppress human tumor growth in nude mouse xenografts. Oncogene 1998; 16 (11): 1467-73.
9. Lobell RB, Omer CA, Abrams MT et al. Evaluation of farnesyl: Protein transferase and geranylgeranyl: Protein transferase inhibitor combinations in preclinical models. Cancer Res 2001; 61 (24): 8758-68.
10. Kainuma O, Asano T, Hasegawa M et al. Inhibition of growth and invasive activity of human pancreatic cancer cells by a farnesyltransferase inhibitor, manumycin. Pancreas 1997; 15 (4): 379-83.
11. Nam J-S, Ino Y, Sakamoto M, Hirohashi S. Ras farnesylation inhibitor FTI-277 restores the E-cadherin/catenin cell adhesion system in human cancer cells and reduces cancer metastasis. Jpn J Cancer Res 2002; 93 (9); 1020-8.
12. Akedo H, Shinkai K, Mukai M et al. Interaction of rat ascites hepatoma cells with cultured mesothelial cell layers: A model for tumor invasion. Cancer Res 1986; 46 (5): 2416-22.
13. Imamura F, Shinkai K, Mukai M et al. Rho-mediated protein tyrosine phosphorylation in lysophosphatidic-acid-induced tumor-cell invasion. Int J Cancer 1996; 65 (5): 627-32.
14. Yoshioka K, Matsumura F, Akedo H, Itoh K. Small GTP-binding protein Rho stimulates the actomyosin system, leading to invasion of tumor cells. J Biol Chem 1998; 273 (9): 5146-54.
15. Yoshioka K, Nakamori S, Itoh K. Overexpression of small GTP-binding protein RhoA promotes invasion of tumor cells. Cancer Res. 1999; 59 (8): 2004-10.
16. Fritz G, Just I, Kaina B. Rho GTPases are over-expressed in human tumors. Int J Cancer 1999; 81 (5): 682-7.
17. Quinn LA, Moore GE, Morgan RT, Woods LK. Cell lines from human colon carcinoma with unusual cell products, double minutes, and homogeneously staining regions. Cancer Res 1979; 39 (12): 4914-24.
18. Pronk GJ, Bos JL. The role of p21ras in receptor tyrosine kinase signaling. Biochim Biophys Acta 1994; 1198 (2-3): 131-47.
19. Kohl NE, Mosser SD, deSolms SJ et al. Selective inhibition of ras-dependent transformation by a farnesyltransferase inhibitor. Science 1993; 260 (5116): 1934-7.
20. Whyte DB, Kirschmeier P, Hockenberry TN et al. K- and N-Ras are geranylgeranylated in cells treated with farnesyl protein transferase inhibitors. J Biol Chem 1997; 272 (22): 14459-64.
21. Rowell CA, Kowalczyk JJ, Lewis MD, Garcia AM. Direct demonstration of geranylgeranylation and farnesylation of Ki-Ras in vivo. J Biol Chem 1997; 272 (22): 14093-7.
22. Di Paolo A, Danesi R, Nardini D et al. Manumycin inhibits ras signal transduction pathway and induces apoptosis in COLO320-DM human colon tumour cells. Br J Cancer 2000; 82 (4): 905-12.
23. Sebti SM, Hamilton AD. Farnesyltransferase and geranylgeranyl- transferase I inhibitors and cancer therapy: Lessons from mechanism and bench-to-bedside translational studies. Oncogene 2000; 19 (56): 6584-93.